PTC Therapeutics, which develops orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, withdrew its filing for IPO Friday citing market conditions. The company had originally filed for IPO in March of 2006. Morgan Stanley and JPMorgan were bookrunning the deal.
